Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US74587B1017
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00BRBHVD0
PLSE
Pulse Biosciences Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $PLNG
NAME
Pulse Biosciences Inc
ISIN
US74587B1017
TICKER
PLSE
MIC
XNAS
REUTERS
PLSE.OQ
BLOOMBERG
PLSE US
Thu, 03.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certai...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.03.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - March 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.03.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - March 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 28, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Pulse securities between...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sun, 27.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 26, 2022) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period") of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Sat, 26.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period"). A class action l...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 24, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 24, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period"). A class action lawsu...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 23.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.02.2022       Pulse Biosciences
US74587B1017

San Diego, California--(Newsfile Corp. - February 17, 2022) - Shareholder Rights Law Firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) who purchased Pulse securities between January 12, 2021 and February 7, 2022, both dates inclus...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 10, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.02.2022       Pulse Biosciences
US74587B1017

Atlanta, Georgia--(Newsfile Corp. - February 8, 2022) -  Holzer & Holzer, LLC is investigating whether Pulse Biosciences, Inc. ("Pulse Biosciences" or the "Company") (NASDAQ: PLSE) complied with federal securities laws. On February 8, 2022, Pulse Biosciences provided an update on the Company's recent 510(k) submission, which a...
Read more
Pulse Biosciences
Technical Analysis Termsheets Terminal
Permalink